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Abstract 
Bleeding complications in dengue may occur irrespective of the presence of plasma leakage. We compared plasma levels of modulators of 
the endothelial barrier among three dengue groups: bleedings without plasma leakage, dengue hemorrhagic fever, and non-complicated 
dengue. The aim was to evaluate whether the presence of subtle alterations in microvascular permeability could be detected in bleeding 
patients. Plasma levels of VEGF-A and its soluble receptors were not associated with the occurrence of bleeding in patients without plasma 
leakage. These results provide additional rationale for considering bleeding as a complication independent of endothelial barrier breakdown, 
as proposed by the 2009 WHO classification. 
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Introduction 
In 2009, a new dengue classification was proposed 
by the World Health Organization (WHO) to improve 
the detection of potentially severe complications of 
this disease, the so-called “warning signs” [1]. 
However, one of the possible limitations for the 
implementation of this classification on a routine basis 
is the fact that the biological rationale supporting the 
categories utilized has not been fully elucidated.  
Bleeding is a common complication of dengue [2]; 
it has been traditionally described along with plasma 
leakage due to increased vascular permeability, and 
thrombocytopenia, as a syndrome known as dengue 
hemorrhagic fever (DHF) [3,4]. In the revised WHO 
classification, bleeding manifestations appear as 
independent dengue complications, but the 
mechanisms of bleeding in patients without plasma 
leakage are not fully understood. Although 
thrombocytopenia and an acquired coagulopathy could 
explain these manifestations [5,6], it is not possible to 
rule out that patients without plasma leakage were 
presenting subtle alterations in endothelial barrier 
function that were not detected by methods used in the 
clinical arena. 
Vascular endothelial growth factor (VEGF)-A is a 
molecule involved in angiogenesis and is a potent 
modulator of the endothelial barrier, likely by 
promoting the destabilization of intercellular junctions 
[7]. At least two of the VEGF-A receptors are 
expressed on endothelial cells, VEGFR-1 and 
VEGFR-2. The binding of VEGF-A to VEGFR-2 on 
the cell membrane leads to an increase in vascular 
permeability [8]. Besides the transmembrane form, 
both receptors also have soluble forms that are 
believed to act as decoy receptors. Soluble VEGFR-1 
binds in vitro to VEGF-A, blocking its interaction with 
cell surface receptors [9], thus balancing its deleterious 
effects [10]. The function of the soluble receptor 
sVEGF-R2 is less known, but it is possible that it 
regulates VEGF-A signaling on endothelial cells by a 
similar mechanism [11].  
The modulation of the endothelial barrier by 
VEGF-A and its soluble decoy receptor, sVEGFR-2, 
has been recently detected as a possible mechanism 
involved in the pathogenesis of DHF. It has been 
demonstrated in vitro that dengue virus could 
downregulate the expression of sVEGF-R2 by the 
endothelial cells, promoting an excess of free VEGF-A 
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and contributing to the occurrence of plasma leakage 
[12].  
Therefore, the aim of this study was to evaluate if 
patients with bleeding manifestations, but without the 
classical clinical and laboratory signs of plasma 
leakage, may present pathological changes in 
modulators of the endothelial barrier similar to those 
found in DHF. The rationale for the study was to 
evaluate biological mechanisms that may discriminate 
dengue with bleeding complications from DHF, as 
clinically suggested by the 2009 WHO classification. 
 
Methodology 
The circulating levels of VEGF-A, sVEGFR-1, 
and sVEGFR-2 in patients with dengue were 
evaluated; the patients presenting with bleeding 
complications without plasma leakage were compared 
with those with bleeding and plasma leakage 
(classified as DHF) and with patients with non-
complicated dengue. 
Patients with suspected dengue infection were 
selected during distinct outbreaks of dengue in 
southeast Brazil, in the cities of Rio de Janeiro in 
2008, and Campinas in 2010, in two different hospitals 
and three primary care medical centers. Dengue 
infection was confirmed when anti-dengue IgM tested 
positive, after the fifth day of fever onset.  
The inclusion criteria were suspected dengue 
infection, age over 17 years, and being in the 
defervescence period. The defervescence period was 
detected according to the medical follow-up at the 
primary care medical centers or at the hospitals. 
Usually, patients were enrolled in the study on the day 
they were tested for dengue serology (after the fifth 
day of fever), according to the Brazilian Ministry of 
Health protocol. Patients who met the inclusion 
criteria were reported to the study personnel, who 
evaluated if the patients could be enrolled in the study. 
After enrollment, patients were followed up 
prospectively until recovery. 
Exclusion criteria were chronic kidney or liver 
disease, autoimmune or chronic infectious disease, 
hematological disorders, and neoplasia. Pregnant 
women were excluded. Patients who did not follow up 
after enrollment were excluded. When the serology 
results were available, patients with negative anti-
dengue IgM were excluded. 
The serological tests for the detection of anti-
dengue virus IgM and IgG antibodies were performed 
by enzyme-linked immunosorbent assay (ELISA) with 
commercial kits (Panbio Dengue, Alere, 
Massachusetts, USA), and were conducted at the 
public health referral laboratories. Patients with 
positive anti-IgM were diagnosed with dengue. 
Blood samples for the study tests were collected 
on the day of enrollment in the study. The study was 
conducted in compliance with the Helsinki 
Declaration, and was approved by the Research Ethics 
Committee of the Faculty of Medical Sciences of the 
University of Campinas. Written informed consent 
was obtained from patients or their relatives before 
any study procedure. Plasma levels of VEGF and its 
soluble receptors, sVEGFR-1 and sVEGFR-2, were 
determined by commercially available ELISA assays 
(Quantikine, R&D Systems, Minneapolis, USA). 
In addition, because sVEGFR-1 and -2 may 
modulate VEGF-A activity, the ratio between VEGF-
A and its soluble receptors was also calculated, in 
order to obtain additional information about the 
activity of the VEGF-A pathway in the regulation of 
endothelial barrier integrity. The ratio between VEGF-
A and its soluble receptors was calculated by dividing 
the plasma concentration of VEGF-A by the plasma 
concentration of the decoy receptors sVEGFR-1 and 
sVEGFR-2, as previously described [13]. 
To compare continuous variables among three or 
more groups, Kruskal-Wallis analysis was used, 
followed by the Tukey test to identify the differences, 
when necessary. Data were analyzed using SPSS for 
Windows version 10.0 (SPSS Inc, Chicago, IL, USA) 
and SAS System for Windows version 9.2 (SAS 
Institute Inc, Cary, NC, USA). Graphics were made 
using GraphPad Prism, version 4 for Windows 
(GraphPad Software Inc., La Jolla, CA, USA). P < 
0.05 was considered statistically significant.  
 
Results 
Three hundred and nineteen adult patients 
presented with suspected dengue infection in the 
period of the study; 63 patients were hospitalized 
because of complications, and 256 attended the 
primary care medical centers. From the 63 patients 
with complications who were hospitalized, 6 refused 
to participate, 14 had signs of convalescence (bleeding 
cessation and platelet arise), and 7 were anti-dengue 
IgM negative; these patients were excluded. From the 
36 patients included, 10 were classified as having 
dengue hemorrhagic fever and 26 patients as having 
dengue fever and spontaneous bleeding, according to 
the traditional WHO classification [3]. From the 256 
patients who attended the primary care centers, 178 
patients were not enrolled in the study because they 
were in the febrile phase of dengue, did not collect 
anti-dengue serology, or lost the follow-up.  




Table 1. Complete blood count and levels of microvascular permeability modulators 
Parameters† 
Dengue with bleeding/no 
plasma leakage 
(n = 26) 
Non-complicated dengue 
(n = 33) 
DHF 
(n = 10) 
P 
Days from the onset of fever 6.5 (1-14) 6 (3-10) 6 (3-11) 0.4 
Hemoglobin, g/dL 13.6 (12.6-14.6) 14.7 (13.6-15.6) 13.8 (11.8-15.5) 0.12 
Hematocrit, % 43.0 (37.0-45.0) 43.3 (40.6-46.3) 40.0 (36.0-50.0) 0.42 
Leucocytes, /mm3 5600 (4700-7660) 4040 (3385-6300) 6000 (4075-6540) 0.17 
Platelets × 109/L 21 (14-36) 203 (126-283) * 17 (11-22) <0.0001 
VEGF-A pg/mL 31.9 (16.8 -60.4) 38.33 (26.8-60.3) 55.9 (32.9-74.4) 0.17 
VEGFR-1 pg/mL 220.6 (150.5-338.3) 178.0 (140.1-221.3) 258.0 (135.6-328.8) 0.17 
VEGFR-2 pg/mL 3,741(2,719-4,312) 4,609 (3,979-5,305)* 2,682 (1,357-4,287) * 0.0002 
VEGF-A/VEGFR-1 0.13 (0.06-0.32) 0.23 (0.12-0.28) 0.23 (0.10-0.47) 0.26 
VEGF-A/VEGFR-2 0.88 (0.2-5.55) 0.83 (0.09-2.75) 1.81 (0.86-10.9) * 0.019 
†Median and interquartile range. Values represent the nadir hematocrit and platelet counts obtained during the defervescence. 
P values were calculated using the Kruskal-Wallis analysis to compare the three groups of dengue patients, and were followed by the Tukey post-test.  
*Place of difference in comparison with the group of dengue fever with bleeding but without plasma leakage detected by the Tukey post-test 
Figure 1. Plasma levels of modulators of microvascular permeability.  
Plasma levels of modulators of microvascular permeability in dengue patients. A. VEGF-A, B. sVEGFR-1, C. sVEGFR-2, D. VEGF-A/sVEGFR-2 
ratio. P values were calculated using the Kruskal-Wallis analysis to compare the three groups of dengue patients, followed by the Tukey post-test to 
detect the place of differences. *Place of differences detected by the Tukey post-test.  
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One patient had chronic myeloid leukemia, one patient 
had a previous history of idiopathic thrombocytopenic 
purpura, three patients had chronic kidney disease, 
eighteen refused to participate, and five blood samples 
were handled inadequately; these were all excluded 
from the study. From the 50 patients who were 
included, 33 had positive anti-dengue IgM. All were 
classified as non-complicated dengue fever according 
to the traditional WHO classification [3]. 
Sixty-nine patients were included in the study; 26 
patients had bleeding complications without plasma 
leakage, 33 had non-complicated dengue infection, 
and 10 had DHF. All patients were included around 
the sixth day after the onset of fever, during the 
defervescence period, as shown in Table 1. 
Bleeding severity was similar between patients 
without plasma leakage and patients with DHF. Mild 
bleeding events, such as petechiae, ecchymosis, 
epistaxis, and gingivorrhagia occurred in 16/26 
patients without plasma leakage (61.5%) and in 7/10 
patients with DHF (70%). Moderate bleeding events, 
such as hemoptysis, hematemesis, hypermenorrhea, 
hematuria, and melena occurred in 10/26 patients 
without plasma leakage (38.5%) and in 3/10 patients 
with DHF (30%). The results of blood counts and 
modulators of microvascular permeability are shown 
in Table 1. Modulators of microvascular permeability 
are also illustrated in Figure 1. 
As demonstrated in Table 1, patients with bleeding 
complications without plasma leakage did not present 
significant changes in VEGF-A or sVEGFR-1 levels. 
The only significant change observed in these patients 
was a lower level of sVEGFR-2 compared to non-
bleeding patients, as shown by the Tukey post-test. 
However, the VEGF-A/sVEGFR-2 ratio was not 
altered in this group of patients. On the other hand, a 
shift towards the activation of the VEGF-A pathway in 
DHF could be observed by a non-significant increase 
in plasma VEGF-A levels, coupled with a more than 
twofold increase in the VEGF-A/sVEGFR-2 ratio (p = 
0.019) in these patients compared to the others.  
 
Discussion 
In the present study, dengue patients with bleeding 
complications were evaluated for the presence of 
changes in modulators of the endothelial barrier. 
Given that the bleeding manifestations in patients with 
dengue are commonly accompanied by increased 
vascular permeability and plasma leakage, we 
hypothesized that more subtle changes in 
microvascular permeability, not detected by the 
classical clinical and laboratory evaluations, could be 
present in bleeding patients without plasma leakage, 
evidencing that these patients suffer a pathological 
mechanism similar to what is suggested in patients 
with DHF. The discrimination of bleeding and plasma 
leakage as two distinct dengue complications, as 
proposed by the 2009 WHO classification, may not be 
adequate for diagnosis and treatment purposes if both 
complications are biologically similar. 
Increased VEGF-A levels have been described in 
patients with conditions associated with disruption of 
the endothelial barrier, such as septic shock [14]. In 
the context of dengue, it has been demonstrated that 
dengue virus could down-regulate the secretion of 
sVEGFR-2 by endothelial cells, thus promoting an 
increase in microvascular permeability via excess of 
circulating VEGF-A [15,16]. Indeed, clinical studies 
have demonstrated that patients with DHF may present 
high levels of VEGF-A [17] and low levels of 
sVEGFR-2 [15,18]. Accordingly, it has been 
suggested that plasma leakage occurring in this 
context could also contribute to occurrences of 
bleeding [19]. 
In our study, similar to that found in the previous 
reports cited above, higher VEGF-A levels were 
observed in patients with DHF, and a more than 
twofold higher VEGF-A/sVEGFR-2 ratio was 
observed in patients with DHF compared to the other 
groups. Dengue patients without plasma leakage did 
not present significant changes in plasma levels of 
VEGF-A and its soluble receptors, suggesting that the 
bleeding complications in these patients were indeed 
not associated with increased vascular permeability. 
To our knowledge, the role of the modulators of the 
endothelial barrier has not previously been evaluated 
in non-dengue hemorrhagic fever syndromes. 
Therefore, according to our results, plasma levels 
of modulators of the endothelial barrier may not be 
associated with the occurrence of bleeding in patients 
with dengue without signs of plasma leakage, 
suggesting that, different from what was found in 
DHF, disruption of the endothelial barrier is not 
involved in the pathogenesis of bleeding 
manifestations in these patients.  
It is important, also, to point out that the sample 
size may have influenced the results. The small sample 
size is justified because patients were selected in a late 
phase of the disease and many lost the follow-up 
before the time of enrollment. However, this study did 
not have epidemiological purposes, and the sample 
size had enough power to show the differences in 
modulators of endothelial barrier bleeding patients, 
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with and without plasma leakage, because these 
differences were very significant. 
These results may confirm that bleeding is a 
dengue complication independent of changes in 
endothelial barrier function, as proposed by the new 
WHO classification [1]. While raising additional 
questions about the mechanisms of bleeding in these 
patients, these results support the implementation of 
the new dengue classification proposed by the WHO. 
 
Conclusion 
Bleeding complications in dengue infections (other 
than DHF) may not be associated with increased 
vascular permeability detected by circulating levels of 
modulators of the endothelial barrier. 
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